| Primary |
| Echinococciasis |
23.4% |
| Enterobiasis |
16.2% |
| Helminthic Infection |
11.7% |
| Product Used For Unknown Indication |
11.7% |
| Hepatic Echinococciasis |
6.3% |
| Asthma |
4.5% |
| Drug Abuse |
4.5% |
| Drug Use For Unknown Indication |
3.6% |
| Malignant Melanoma |
3.6% |
| Anti-infective Therapy |
2.7% |
| Attention Deficit/hyperactivity Disorder |
1.8% |
| Infection Parasitic |
1.8% |
| Nasopharyngitis |
1.8% |
| Epilepsy |
0.9% |
| Foetal Exposure During Pregnancy |
0.9% |
| Ill-defined Disorder |
0.9% |
| Medication Error |
0.9% |
| Strongyloidiasis |
0.9% |
| Tonsillitis |
0.9% |
| Toxocariasis |
0.9% |
|
| Abdominal Pain |
11.4% |
| Foetal Exposure During Pregnancy |
9.1% |
| Granulocytopenia |
6.8% |
| Respiratory Failure |
6.8% |
| Therapeutic Response Decreased |
6.8% |
| Blister |
4.5% |
| Drug Ineffective |
4.5% |
| Haematotoxicity |
4.5% |
| Haemorrhage |
4.5% |
| Hallucination |
4.5% |
| Hypersensitivity |
4.5% |
| Muscular Weakness |
4.5% |
| Nausea |
4.5% |
| Red Blood Cell Count Decreased |
4.5% |
| Tachycardia |
4.5% |
| Vomiting |
4.5% |
| Agranulocytosis |
2.3% |
| Anaphylactic Reaction |
2.3% |
| Anaphylactic Shock |
2.3% |
| Angioedema |
2.3% |
|
| Secondary |
| Product Used For Unknown Indication |
25.8% |
| Drug Abuse |
16.1% |
| Attention Deficit/hyperactivity Disorder |
12.9% |
| Onchocerciasis |
12.9% |
| Blood Disorder |
6.5% |
| Helminthic Infection |
6.5% |
| Malignant Melanoma |
6.5% |
| Worms |
6.5% |
| Enterobiasis |
3.2% |
| Infection Parasitic |
3.2% |
|
| Off Label Use |
15.4% |
| Pharyngeal Erythema |
15.4% |
| Anaphylactic Reaction |
7.7% |
| Blister |
7.7% |
| Dystonia |
7.7% |
| Generalised Anxiety Disorder |
7.7% |
| Hallucination |
7.7% |
| Musculoskeletal Stiffness |
7.7% |
| Obsessive-compulsive Personality Disorder |
7.7% |
| Overdose |
7.7% |
| Vitiligo |
7.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
46.1% |
| Drug Exposure During Pregnancy |
9.0% |
| Hiv Infection |
8.4% |
| Menstrual Cycle Management |
4.8% |
| Contraception |
4.2% |
| Enterobiasis |
3.0% |
| Prophylaxis |
3.0% |
| Glioblastoma Multiforme |
2.4% |
| Polycystic Ovaries |
2.4% |
| Antiviral Treatment |
1.8% |
| Eructation |
1.8% |
| Helminthic Infection |
1.8% |
| Neuropathy Peripheral |
1.8% |
| Pain |
1.8% |
| Pyrexia |
1.8% |
| Anaemia |
1.2% |
| Asthma |
1.2% |
| Back Pain |
1.2% |
| Blood Thyroid Stimulating Hormone Increased |
1.2% |
| Bronchitis |
1.2% |
|
| Stillbirth |
8.6% |
| Ventricular Hypoplasia |
8.6% |
| Breast Cancer Female |
5.7% |
| Diarrhoea |
5.7% |
| Drug Exposure During Pregnancy |
5.7% |
| Hypertension |
5.7% |
| Left Ventricular Hypertrophy |
5.7% |
| Rash |
5.7% |
| Tachycardia |
5.7% |
| Thinking Abnormal |
5.7% |
| Ventricular Tachycardia |
5.7% |
| Vomiting |
5.7% |
| White Blood Cells Urine Positive |
5.7% |
| Anhedonia |
2.9% |
| Arthralgia |
2.9% |
| Breast Cancer |
2.9% |
| Bullous Impetigo |
2.9% |
| Deep Vein Thrombosis |
2.9% |
| Drug Ineffective |
2.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.9% |
|
| Interacting |
|
|
